Stocktwits on MSN
Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results
An investigational intravesical drug-releasing system with erdafitinib is designed to provide prolonged release of erdafitinib directly into the bladder via intravesical administration. ・The company ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Pfizer and Astellas Pharma said a treatment for certain bladder-cancer patients demonstrated positive topline results in a Phase 3 study. In the trial, the combination of Padcev with Merck & Co.'s ...
Keytruda and Padcev combination improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy. The KEYNOTE-905 trial showed significant event-free survival ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results